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Objective: Sclerostin inhibits osteoblast differentiation and bone formation. If aberrant sclerostin action
is involved in less efficient bone acquisition in men with idiopathic low bone mass, this might be
reflected in higher serum sclerostin levels.
Methods: In 116 men with idiopathic osteoporosis (%65 years old), 40 of their sons and healthy
controls, areal bone parameters were measured using dual-energy X-ray absorptiometry, and
volumetric and geometric bone parameters were measured using peripheral quantitative computed
tomography. Serum analytes were measured using immunoassays and estradiol (E2) levels using liquid
chromatography–tandem mass spectrometry.
Results: Men with idiopathic low bone mass had lower levels of sclerostin than the controls (0.54G
0.17 vs 0.66G0.23 ng/ml; P!0.001). In both groups, sclerostin levels were strongly associated with
age; when adjusting for age, no associations with anthropometrics were observed (PO0.14). In
multivariate analyses, sclerostin levels displayed a positive association with whole-body bone mineral
content (BMC) and areal BMD (aBMD), as well as with trabecular and cortical volumetric bone mineral
density (vBMD) at the tibia in the probands. No clear associations were observed in the control group,
neither were sclerostin levels associated with BMC at the radius or lumbar spine (all PO0.11).
Testosterone, but not E2, was inversely related to sclerostin levels in the probands. No difference in
sclerostin levels was found in their sons when compared with their controls.
Conclusion: Lower rather than higher serum sclerostin levels in the probands with idiopathic low bone
mass suggest that aberrant sclerostin secretion is not involved in the pathogenesis of low bone mass in
these subjects.
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Osteoporosis and related fractures are prevalent and
lead to increased morbidity and mortality in both sexes
(1). In about half of men with osteoporosis, no clear
pathogenic cause can be established (2). Our previous
findings in a family-based study of men with idiopathic
osteoporosis concurred to indicate the existence of a
familial defect in the acquisition of bone mass and size,
involving both trabecular and cortical bone.
Sclerostin, a glycoprotein secreted by osteocytes
partially in response to mechanical loading, is a strong
negative regulator of osteoblast differentiation and
bone formation through antagonizing effects on the
Wnt/b-catenin signaling pathway (3, 4). Serum levels
of sclerostin increase with aging, have been reported to
be positively related to overall bone mass, and sex
differences have been described (5, 6, 7, 8). Further-
more, observational and interventional data suggest
that circulating sclerostin levels are modulated by
estrogen exposure (6, 7, 8, 9). In our family-based
study, we reported lower serum estradiol (E2) levels inndocrinologymen with idiopathic low bone mass, suggesting an
estrogen-related factor in the pathogenesis of male
idiopathic osteoporosis. In addition, these men displayed
lower serum pro-collagen 1 amino-terminal propeptide
(P1NP) levels, reflecting less bone formation (10, 11).
We therefore hypothesized that lower bone mass in
these men might result from constitutionally higher
sclerostin levels and/or action, possibly linked to lower
E2 exposition at the tissue level.Materials and methods
Subjects
Male study subjects (nZ116) were diagnosed with
idiopathic low bone mass using the following inclusion
criteria: age%65 years at presentation and areal BMD
(aBMD) Z-score %K2.0 at the lumbar spine or
proximal femur. Extensive clinical and laboratory
investigations excluded secondary causes of low bone
mass. All sons were invited to participate without anyDOI: 10.1530/EJE-12-1074
Online version via www.eje-online.org
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hyperthyroidism, metabolic bone disease, delayed pub-
erty, current or past alcohol consumption of R5
units/day more than once weekly, malabsorption,
hemochromatosis, renal or gonadal dysfunction, malig-
nancy or chronically treated with glucocorticoids,
levothyroxin, or (anti)androgens were excluded. For
each proband and son, a gender- and age-matched (G2
years) control was recruited among healthy volunteers
without a family history of osteoporotic fractures. None
had a history of disease or medication use interfering
with bone metabolism, or were heavy smokers (R40
pack-years) or drinkers (R5 units/day more than once
weekly). Physical activity was assessed by recording the
weekly frequency of recreational and/or professional
activities and scored as proposed by Baecke et al. (12).
All participants gave written informed consent for
participation in this study, approved by the ethics
review board of the Ghent University Hospital.Anthropometrics, soft tissue composition,
and areal bone parameters
Participants’ body weight was measured to the nearest
0.5 kg in light indoor clothing without shoes. Standing
height was measured to the nearest 0.1 cm using a
wall-mounted Harpenden stadiometer. Areal bone
parameters at the lumbar spine, proximal femur (total
hip and neck), radius (non-dominant side), and whole-
body composition were measured using DXA:
QDR-2000 (first 68 matched couples; software version
7.20) or QDR-4500A (all subsequent couples; software
version 11.2.1; Hologic, Inc., Bedford, MA, USA); all
matched couples were measured on the same device
and devices were cross-calibrated. Vertebrae with
apparent fractures were excluded from the analysis;
coefficients of variation (CV) were !1% for daily spine
and weekly whole-body phantom measurements.pQCT measurements
In this ongoing study, peripheral quantitative computed
tomography (pQCT) measurements were added and
extended during the study course and lack for some of
the early recruited probands and their sons. Cross-
sectional slices (2.0 mm thick; voxel size 0.4 mm) at the
metaphysis (at 4% of bone length from the distal end of
the radius) of the non-dominant forearm (all partici-
pants) and the lower leg (probands only, 66 couples)
were taken to determine trabecular volumetric bone
mineral density (vBMD) by pQCT (XCT2000; Stratec
GmbH, Pforzheim, Germany). Cortical bone parameters
were determined at the midshaft of the non-dominant
forearm (probands, 70 couples and sons, 23 couples)
and the lower leg (probands, 66 couples) at 33 and 38%
of bone length from the distal end of the radius and tibia
respectively. Analyses were performed using the man-
ufacturer’s software (version 5.4). The cross-sectionalwww.eje-online.orgarea of the radius/tibia was determined after detecting
the outer bone contour at a threshold of 280 mg/cm3.
The threshold was set at 180 mg/cm3 for determining
trabecular vBMD and at 710 mg/cm3 for cortical bone.
Cortical thickness and the endo- and periosteal
circumference were estimated using the circular ring
model in which the shaft of a long bone is assumed to be
an ideal cylinder.Laboratory measurements
Venous blood was obtained between 0800 and 1000 h
after overnight fasting and serum stored at K80 8C
until analysis. Samples from the probands, their sons,
and respective controls were measured in a single assay
run. Commercial immunoassays were used to measure
serum leptin (Linco Research, Inc., MO, USA), P1NP,
total testosterone, SHBG (Orion Diagnostica, Espoo,
Finland), C-terminal telopeptides of type 1 collagen
(CTX; Biomedica Medizinprodukte GmbH, Vienna,
Austria), bone-specific alkaline phosphatase (bAP;
Beckman Coulter, Inc., Fullerton, CA, USA), osteocalcin
(Nordic Bioscience Diagnostics A/S, Herlev, Denmark),
and sclerostin (TECOmedical AG, Sissach, Switzerland).
For sclerostin, the limit of detection was 0.12 ng/ml and
the limit of quantification 0.20 ng/ml; intra-assay
CV was!15% for levels between 0.20 and 0.50 ng/ml
and !6% for levels O1.00 ng/ml and inter-assay CV
was !6% for levels O0.50 ng/ml. Serum E2 was
determined by liquid chromatography–tandem mass
spectrometryas described previously (13). Free testoster-
one and E2 were calculated from testosterone, E2, SHBG,
and albumin concentrations using equations based on
the mass action law (14, 15). For all measurements,
intra- and inter-assay CV were below 10 and 15%
respectively. Assayswere performed at the Laboratory for
Hormonology at the Ghent University Hospital except
for serum sclerostin, which was assayed at the Bone and
Cartilage Markers Laboratory, Unilab Lg, CHU Sart
Tilman, University of Lie`ge. Kidney function was
determined by the calculation of estimated glomerular
filtration rate (eGFR; ml/min per 1.73 m2) according to
the MDRD formula.Statistical analysis
If normally distributed, variables were described as
meanGS.D., and as median (1st–3rd quartiles) other-
wise. If necessary, variables were transformed (natural
logarithmic) to meet the required model assumptions.
Comparisons between groups were performed using
independent sample t-tests and ANCOVAs to account for
potential confounding by age, body weight, or height.
Univariate and age-, weight-, and height-adjusted
associations between sclerostin and different patients’
characteristics were explored using multiple linear reg-
ression models, with effect estimates reported as stan-
dardized regression coefficients (b). The level indicating
Table 1 General and bone parameters. Data presented as meanGS.D.
Probands
(nZ116)
Controls
(nZ116) Pa Sons (nZ40)
Controls
(nZ40) Pa
Age (years) 45.3G12.9 46.0G13.1 0.68 28.6G6.0 28.8G6.4 0.91
Weight (kg) 74.4G9.3 82.3G11.6 !0.001 73.5G11.3 79.1G10.0 0.087
Height (cm) 174.4G6.3 177.1G6.5 0.002 180.8G6.7 180.8G6.1 0.99
Trabecular vBMD at radius 4% (g/cm3)b 183G37 226G43 !0.001 217G32 242G38 0.036
Cortical vBMD at radius 66% (g/cm3) 1191G50 1207G22 0.004 1178G59 1197G46 0.32
Cortical bone area at radius 66% (cm2) 94G13 103G13 !0.001 97G10 105G12 0.072
aAccording to an independent Student’s t-test.
bpQCT data only available for 23 of the sons.
Sclerostin levels and idiopathic osteoporosis 617EUROPEAN JOURNAL OF ENDOCRINOLOGY (2013) 168statistical significance was !0.05 (two-tailed).
Statistical analyses were performed using SPSS
(version 19.0; SPSS, Inc.).Results
General characteristics
As reported previously (11), men with idiopathic
osteoporosis had a lower body weight, height, lean,
and fat mass than the age-matched control subjects.
Their bone mass deficit involved trabecular and cortical
bone density as well as cortical bone size (Table 1), and
these men presented lower serum levels of E2 and free
E2, in part due to higher SHBG levels (Table 2).
Regarding sclerostin, lower serum levels were observed
in men with idiopathic osteoporosis when compared
with their controls (Fig. 1), whereas no difference was
found in their sons when compared with their
respective controls. The results were not essentially
different when only considering the affected sons (data
not shown). When adjusting for age and whole-body
BMC, the observed between-group difference in serum
sclerostin levels between the probands and their
controls was no longer significant (PZ0.13).Relationship with serum sclerostin levels
In both probands and healthy controls, sclerostin levels
were strongly and essentially similarly related to age
(Fig. 2). In the control group, positive associationsTable 2 Serum sclerostin and sex steroid levels.
Probands
(nZ116)
Controls
(nZ116)
Sclerostin (ng/ml) 0.54 (0.41–0.66) 0.61 (0.51–0.78)
SHBG (nmol/l)a 29.6 (22.9–37.4) 25.8 (20.2–37.1)
Testosterone (ng/dl) 537G163 554G157
Free testosterone (ng/dl) 11.5G3.8 12.9G4.2
Estradiol (E2; pg/ml) 17.4G5.4 21.9G6.2
Free E2 (pg/ml) 0.32G0.12 0.43G0.15
Data presented as meanGS.D., unless a: presented as median (1st–3rd quartile
Student’s t-test or a Wilcoxon signed-rank test, where appropriate. Conversion fa
pmol/l is 3.671.between sclerostin levels and body weight, BMI, and
total fat mass were no longer significant after adjusting
for age, whereas positive associations with leptin levels
persisted even after controlling for weight or body
fat mass (probands, bZ0.341; PZ0.062 and controls,
bZ0.265; PZ0.037; Table 3).
When adjusting for age, weight, and height, scler-
ostin levels in the probands were positively related to
whole-body aBMD and BMC, as well as to trabecular
vBMD and BMC and cortical vBMD at the tibia. In the
controls, sclerostin levels were associated with aBMD at
the proximal femur and tended to be positively related to
cortical vBMD (bZ0.228; PZ0.057). No associations
were found with trabecular or cortical bone parameters
at the radius, neither were sclerostin levels associated
with areal bone parameters at the radius or lumbar
spine in either group (all PO0.06). Except for the
endosteal circumference at the tibia (bZK0.23;
PZ0.032) in the probands, no significant associations
between sclerostin levels and bone size parameters were
found. The results were essentially unaltered when
adjusting for lean and/or fat mass instead of weight
(data not shown).
Sclerostin levels were inversely related to the serum
levels of P1NP, CTX, bAP, and osteocalcin in the control
group and to P1NP levels in the probands; findings,
however, were lost after correcting for participant’s age
(data not shown). There was no difference in serum
sclerostin levels between those with and without
previous fractures (PO0.22) in either group, and no
relationship with indices of physical activity was
observed (data not shown; all PO0.19). SerumP * Sons (nZ40) Controls (nZ40) P *
!0.001 0.52 (0.41–0.62) 0.54 (0.45–0.66) 0.31
0.027 29.4 (24.3–36.9) 24.9 (20.4–32.5) 0.14
0.42 585G179 584G1690 0.99
0.009 12.8G4.3 13.6G3.8 0.39
!0.001 19.3G5.1 20.2G5.3 0.47
!0.001 0.37G0.11 0.40G0.11 0.26
s) in the case of a non-Gaussian distribution. *According to an independent
ctor for testosterone from ng/dl to nmol/l is 0.0347, for estradiol from pg/ml to
www.eje-online.org
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Figure 1 Dot plots of serum sclerostin levels in men with idiopathic
osteoporosis and age-matched controls. The full line represents
the mean.
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vitamin D supplements vs those who did not (0.57G
0.16 vs 0.48G0.16; PZ0.007), and sclerostin
levels were inversely related to the eGFR in both groups
(rZK0.26; PZ0.007 and rZK0.26; PZ0.010
respectively). These latter findings lost statistical
significance when adjusting for participant’s age (all
PO0.18).
In the probands, and in the univariate analyses in the
control group, negative associations between serum
sclerostin and both total (rZK0.18; PZ0.047) and free
(rZK0.20; PZ0.031) testosterone levels were found.
No associations with (free) E2 or SHBG levels were found,
but when controlling for testosterone levels, total E2
levels were found to be positively related to sclerostin
levels (bZ0.20; PZ0.039) in the probands only.
In the sons and their respective controls, sclerostin
levels tended to be positively related to total body weight
(age-adjusted bZ0.379; PZ0.098 and bZ0.447;
PZ0.028 respectively), whereas no significant associ-
ations with age, bone parameters, or sex steroids were
found (data not shown).1.2
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Figure 2 Scatterplots of both groups’ age and serum sclerostin
levels.Discussion
Contrary to the initial working hypothesis, lower rather
than higher serum sclerostin levels were observed inmen
with idiopathic low bone mass when compared with
age-matched control subjects. Given that sclerostin is
acknowledged as having anti-proliferative and anti-
differentiating effects on osteoblasts (3, 4), this finding
pleads against the involvement of aberrant sclerostin
secretion in the pathogenesis of low bone mass in these
subjects.
This between-group difference in sclerostin levels was
no longer significant after adjusting for whole-body
BMC, and sclerostin levels were positively related to
parameters reflecting bone strength in the probands andwww.eje-online.org– albeit to a lesser extent – in the controls. Although not
unequivocally (7, 16), earlier studies have also reported
positive associations between serum sclerostin levels and
bone mass in both men and women (5, 7, 8). These
positive associations between bone mass, other par-
ameters of bone strength, and serum sclerostin levels
may seem counterintuitive since sclerostin is considered
to inhibit bone formation. However, they could be
explained by the fact that for the same forces applied,
lower bone mass will lead to higher mechanical strain,
thereby decreasing sclerostin secretion by osteocytes.
Taken together, this suggests that lower serum sclerostin
levels in men with idiopathic osteoporosis reflect their
lower bone mass and osteocyte number or cell mass.
Corroborating previous findings (5, 7, 8, 9, 16), we
also found a strong positive association between serum
sclerostin levels and age. Several in vivo studies have
shown that mechanical loading decreases, whereas
unloading increases local sclerostin production (17,
18, 19). Since aging is associated with less physical
activity and consequently mechanical loading (20, 21),
this might at least partially explain the positive
association between age and sclerostin levels.
Previous studies reported an inverse association
between serum sclerostin and E2 levels in pre- and
postmenopausal women (16), lower sclerostin levels in
postmenopausal women under hormonal replacement
therapy (7, 9), and an interventional study by Mo¨dder
et al. (9) demonstrated that E2 withdrawal increases
serum sclerostin levels in men in whom endogenous sex
steroid production was eliminated and then substituted
at physiological levels. Contrary to what could be
expected from these findings, total E2 levels were
positively related to sclerostin levels when controlling
for testosterone levels in our probands. Further, a
consistent negative association was observed between
sclerostin and both total and free testosterone levels in
our probands, as well as in the univariate analyses in
Table 3 Unadjusted/age-, weight- and height-adjusted standar-
dized regression coefficients (b) between serum sclerostin levels
and general, bone and sex steroid parameters.
Characteristics Probands Controls
Age 0.389§/0.475§,a 0.485§/0.472§,a
Weight 0.084/0.038b 0.197*/0.143b
Height K0.148/0.071c K0.168/K0.005c
BMI 0.142/0.003d 0.292†/0.132d
Lean mass K0.030/0.00b 0.027/0.127b
Fat mass 0.158/0.080b 0.336†/0.156b
eGFR K0.176/0.001 K0.201†/0.007
Leptin 0.280†/0.259* 0.356§/0.189
Whole body BMC 0.037/0.288† 0.076/0.202
Whole body aBMD 0.013/0.267† 0.066/0.194
Lumbar spine BMC K0.081/0.165 0.018/0.114
Lumbar spine aBMD K0.152/0.088 0.014/0.049
Total hip BMC K0.140/K0.166 0.068/0.133
Total hip aBMD K0.150/K0.072 0.064/0.247*
Radius BMC 0.048/0.044 0.012/K0.008
Radius aBMD K0.007/0.116 0.023/0.047
Radius trab. BMC 0.103/0.111 0.039/0.038
Radius trab. vBMD 0.012/0.165 0.042/0.079
Radius cort. BMC 0.010/0.070 0.065/0.093
Radius cort. vBMD K0.113/0.078 K0.079/0.171
Tibia trab. BMC 0.088/0.222* 0.067/0.136
Tibia trab. vBMD 0.024/0.276† 0.055/0.129
Tibia cort. BMC 0.016/0.100 0.066/K0.001
Tibia cort. vBMD 0.049/0.227* K0.112/0.228
Estradiol 0.071/0.110 K0.046/0.106
Free estradiol K0.036/0.008 0.003/0.086
Testosterone K0.186*/K0.184* K0.208*/K0.018
Free trestosterone K0.311†/K0.202* K0.183/0.010
SHBG 0.066/K0.145 K0.096/K0.167
*P!0.05, †P!0.01 and §P!0.001. E2, estradiol.
aAdjusted for weight and height.
bAdjusted for age and height.
cAdjusted for age and weight.
dAdjusted for age.
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cross-sectional studies reporting a positive association
between serum E2 and sclerostin levels in older men
(7, 8) and a negative association between bioavailable
testosterone and sclerostin levels in a middle-aged
subgroup (40–59 years) (7). These inconsistent
findings are difficult to explain but might result from
differences in participants’ conditions, leading to
different sex hormone levels and/or increased bone
remodeling.
The strengths of our study are the well-described
patient population of men with idiopathic osteoporosis,
together with their well-characterized phenotype. Limi-
tations are the limited sample size and the fact that male
idiopathic osteoporosis might represent a spectrum of
low bone mass due to heterogeneous mechanisms and
different causes. Given the age of our probands and
controls, we cannot extrapolate the role of sclerostin
during peak bone mass acquisition. However, given that
no differences in sclerostin levels were observed between
their sons (whether they were affected or not) and age-
matched controls, a primary role for sclerostin in the
deficient bone acquisition process inmenwith idiopathic
osteoporosis seems unlikely.In conclusion, this study shows that serum sclerostin
levels in men with idiopathic osteoporosis are lower
than those in healthy control subjects, possibly
reflecting differences in overall bone mass. Although
further research is needed, aberrant sclerostin secretion
seems unlikely to be causally involved in the patho-
genesis of idiopathic osteoporosis in men.Declaration of interest
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